Social Media Ideas for Novartis Ag

<![CDATA[Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset]]>

<![CDATA[Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Cl...

<![CDATA[Novartis Investors Share Concerns Over M&A Strategy: Report]]>

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

<![CDATA[Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy]]>

<![CDATA[Artisan Partners’ Director Calls for Novartis Board Shake-Up ]]>

StockWatch: Novartis Loses More than Market Value After Phase III Failure

"The party’s over," top shareholder declares, demanding pharma giant’s board keep closer eye on acquisitions; Analysts pinpoint competitors likely to benefit, while some market wat...

<![CDATA[Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials]]>

<![CDATA[Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboa...

Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of the...

Novartis milestones be proud ! Management take a bow !

Novartis milestones be proud ! Management take a bow ! Anonymous (not verified) Tue, 10/13/2026 - 07:11 field_thread_url https://cafepharma.com/boards/thre...

Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-220...

Novartis: The Sell-Off Creates An Attractive Entry Point

<![CDATA[Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche ]]>

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

Novartis Can't Dodge Hedge Fund Trade Secrets Suit

A New York federal judge has denied Novartis' bid to toss an investment management firm's lawsuit accusing the pharmaceutical company and others of helping the firm's former chief...

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

<![CDATA[Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion]]>

<![CDATA[Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somniver...

<![CDATA[Novo Announces Drug Discovery Collaboration with Anthropic ]]>

<![CDATA[Pharmaceutical Executive Daily: Novo Partners with Anthropic]]>

Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...